ADC Therapeutics SA (ADCT)

Price$3.40

Value ScoreD

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-30.72%

Price vs S&P 500 (4W)-16.20%

VGM Score45.36

Market Capitalization$432.45M

All Metrics

Book Value / Share (Quarterly)$0.47

P/TBV (Annual)3.97x

Revenue Growth (3Y)-27.09%

Cash Flow / Share (Quarterly)$-0.90

Price vs S&P 500 (YTD)-14.62%

Gross Margin (TTM)90.71%

Net Profit Margin (TTM)-173.02%

EPS (TTM)$-1.12

10-Day Avg Trading Volume0.81M

EPS Excl Extra (TTM)$-1.12

Revenue Growth (5Y)98.48%

EPS (Annual)$-1.12

ROI (Annual)-37.24%

Gross Margin (Annual)92.87%

Net Profit Margin (5Y Avg)-299.19%

Cash / Share (Quarterly)$1.82

Revenue Growth QoQ (YoY)-9.47%

ROA (Last FY)-44.14%

Revenue Growth TTM (YoY)4.43%

EBITD / Share (TTM)$-0.89

ROE (5Y Avg)-117.97%

Operating Margin (TTM)-149.39%

Cash Flow / Share (Annual)$-1.12

P/B Ratio11.47x

P/B Ratio (Quarterly)4.17x

Net Income / Employee (Annual)$-758,600

EV / Revenue (TTM)7.85x

Net Interest Coverage (TTM)-2.26x

ROA (TTM)-44.70%

EPS Incl Extra (Annual)$-1.12

Current Ratio (Annual)4.37x

Quick Ratio (Quarterly)3.94x

3-Month Avg Trading Volume0.93M

52-Week Price Return22.74%

Revenue / Employee (TTM)$421,100

Tangible BV / Share (Quarterly)$0.30

P/S Ratio (Annual)5.32x

Asset Turnover (Annual)0.25x

52-Week High$4.98

Operating Margin (5Y Avg)-284.41%

EPS Excl Extra (Annual)$-1.12

CapEx CAGR (5Y)-37.69%

Tangible BV CAGR (5Y)-21.14%

26-Week Price Return-14.79%

Quick Ratio (Annual)4.23x

13-Week Price Return-17.68%

Total Debt / Equity (Annual)3.72x

Current Ratio (Quarterly)4.09x

Enterprise Value$621.81M

Revenue / Share Growth (5Y)89.29%

Asset Turnover (TTM)0.26x

Book Value / Share Growth (5Y)-19.47%

Revenue / Employee (Annual)$432,800

Inventory Turnover (Annual)0.51x

Pretax Margin (Annual)-174.06%

Cash / Share (Annual)$2.08

3-Month Return Std Dev60.18%

Gross Margin (5Y Avg)95.14%

Net Income / Employee (TTM)$-728,700

ROE (Last FY)-175.65%

Net Interest Coverage (Annual)-2.32x

EPS Basic Excl Extra (Annual)$-1.12

Receivables Turnover (TTM)2.52x

Total Debt / Equity (Quarterly)9.01x

EPS Incl Extra (TTM)$-1.12

Receivables Turnover (Annual)3.29x

ROI (TTM)-48.19%

P/S Ratio (TTM)5.46x

Pretax Margin (5Y Avg)-298.20%

Revenue / Share (Annual)$0.64

Tangible BV / Share (Annual)$0.92

Price vs S&P 500 (52W)-5.46%

Year-to-Date Return-3.68%

5-Day Price Return0.29%

EPS Normalized (Annual)$-1.12

ROA (5Y Avg)-45.50%

Net Profit Margin (Annual)-175.31%

Month-to-Date Return-10.05%

Cash Flow / Share (TTM)$-2.16

EBITD / Share (Annual)$-0.95

Operating Margin (Annual)-149.34%

LT Debt / Equity (Annual)3.49x

ROI (5Y Avg)-69.52%

LT Debt / Equity (Quarterly)8.32x

EPS Basic Excl Extra (TTM)$-1.12

P/TBV (Quarterly)6.53x

P/B Ratio (Annual)3.33x

Inventory Turnover (TTM)0.66x

Pretax Margin (TTM)-171.95%

Book Value / Share (Annual)$1.10

Price vs S&P 500 (13W)-27.42%

Beta1.76x

Revenue / Share (TTM)$0.51

ROE (TTM)-229.23%

52-Week Low$2.47

vGradeD

gGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.13est. -0.22

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.33

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ADCTADC Therapeutics SA	D	C	C	$3.40
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

ADC Therapeutics is an oncology-focused biotechnology company with an FDA-approved product, ZYNLONTA, for relapsed or refractory large B-cell lymphoma. The company develops antibody-drug conjugates (ADCs) targeting hematological malignancies and solid tumors, supported by a pipeline of candidates across multiple mechanisms. Revenue is generated primarily from the United States and Europe.